Sandoz further asserts leadership in biosimilars, breaking ground on new Slovenia facility to expand European biosimilar hub and global market reach
Basel, July 1, 2025 – Sandoz (SIX:SDZ/OTCQX:SDZNY), the global leader in generic and biosimilar medicines, today announced the start of construction for a new, state-of-the-art biosimilars production center for sterile product manufacturing in Brnik, Slovenia. This USD 440 million project brings the company's total planned and ongoing investment in Slovenia to more than USD 1.1 billion by 2029. It complements ongoing investments in Slovenia, namely a new biosimilar drug substance production center in Lendava and a biosimilar development center in Ljubljana.
The construction start on the new plant marks the latest development in the company's strategic plan to capture a significant part of an unprecedented market opportunity, with the value of biosimilar patent expiries expected to reach USD 222 billion[1] over the next 10 years. The ongoing investments in in-house capabilities to establish a fully integrated European biosimilar hub are in line with the existing capital expenditure (CapEx) commitments related to Sandoz operations in Slovenia.
Richard Saynor, Chief Executive Officer of Sandoz, said: 'Biosimilars is the fastest-growing segment of our pipeline as the need of patients and healthcare systems for these critical medicines continues to grow rapidly. As the global leader in the field, we are investing to meet rapidly growing patient demand. With a commitment of over USD 1.1 billion, we are proud to significantly expand our biosimilar manufacturing capacity in Europe as Slovenia's largest direct foreign investor. This is another major step that will position Sandoz uniquely to capitalize on the unprecedented biosimilars market opportunity of the next decade.'
Glenn Gerecke, Chief Manufacturing and Supply Officer at Sandoz, said: 'Our investment in biomanufacturing in the heart of Europe marks another important milestone in building our own independent manufacturing network – one that enhances our control, resilience and agility across the global supply chain. We recognize the strategic value Slovenia brings for us as a company: a highly skilled talent pool in natural sciences and engineering; a central location with world-class logistics infrastructure; cost-competitive production; and a stable, innovation-driven environment closely connected to academia and research.'
As the global pioneer and leader in biosimilars, with 11 marketed molecules and an industry-leading pipeline of 28 molecules, Sandoz is uniquely placed to seize this opportunity and play a leading role in ensuring continued patient access to these critical medicines. The new high-tech facility in Brnik will focus on the production of injectable products for both the existing and upcoming portfolio of biosimilars. It will include preparation, filling, assembly and packaging of sterile injectable products, along with laboratories for quality control. Designed with the latest technology, the site will enhance the company's ability to deliver high-quality, affordable biosimilars to patients worldwide.
Biosimilars are instrumental to ensuring and expanding patient access to biologic medicines and are indispensable for the long-term sustainability of healthcare systems. They contribute to competitiveness, support the supply of essential medicines and fuel innovation while offering more affordable treatment options. The growth of biosimilars is central to the Sandoz strategic roadmap.
Pictures
Please find here the download link to the image material:
https://www.lek.si/en/media/multimedia-library/new-bioinjectables-production-center-slovenia/
DISCLAIMER
This Media Release contains forward-looking statements, which offer no guarantee with regard to future performance. These statements are made on the basis of management's views and assumptions regarding future events and business performance at the time the statements are made. They are subject to risks and uncertainties including, but not confined to, future global economic conditions, exchange rates, legal provisions, market conditions, activities by competitors and other factors outside of the control of Sandoz. Should one or more of these risks or uncertainties materialize or should underlying assumptions prove incorrect, actual outcomes may vary materially from those forecasted or expected. Each forward-looking statement speaks only as of the date of the particular statement, and Sandoz undertakes no obligation to publicly revise any forward-looking statements, except as required by law.
REFERENCES
[1] Includes LoE in the period from 2024 to 2035 in major markets (US and EU); LoE dates based on IP databases; originator sales data at LoE-1 from internal analysis and Evaluate Pharma (download Nov 2024)
ABOUT SANDOZ
Sandoz (SIX: SDZ; OTCQX: SDZNY) is the global leader in generic and biosimilar medicines, with a growth strategy driven by its Purpose: pioneering access for patients. More than 20,000 people of 100 nationalities work together to ensure 900 million patient treatments are provided by Sandoz, generating substantial global healthcare savings and an even larger social impact. Its leading portfolio of approximately 1,300 products addresses diseases from the common cold to cancer. Headquartered in Basel, Switzerland, Sandoz traces its heritage back to 1886. Its history of breakthroughs includes Calcium Sandoz in 1929, the world's first oral penicillin in 1951, and the world's first biosimilar in 2006. In 2024, Sandoz recorded net sales of USD 10.4 billion.
CONTACTS
Attachment
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
24 minutes ago
- Business Wire
Global Electric Mobility: Insights From BearingPoint and HRI Show Technology on Par, but Market Attractiveness Depends on Infrastructure, Price, and Trust
AMSTERDAM--(BUSINESS WIRE)--As battery electric vehicles (BEVs) reach similar levels of technological maturity worldwide, other factors are now decisive in shaping market attractiveness and influencing consumer purchasing decisions. The new 2025 E-Mobility Attractiveness Index by BearingPoint and the Handelsblatt Research Institute compares for the first time the four major auto markets: China, France, Germany, and the US. The index aims to assess how BEVs are perceived in each market — based on objective data and country-specific surveys of drivers — and to identify the key factors influencing market success. Price, incentives, and power: e-mobility will only reach the mass market when purchase incentives, charging infrastructure, and fair electricity prices come together. Share China leads the index with a score of 133.5 points (baseline 100), followed by the US (114.4), Germany (108.4), and France (94.6). The technological foundation of available BEVs — including range, charging speed, and energy consumption — has become increasingly similar across models in all four countries. As a result, competition is shifting away from the technology itself toward infrastructural and policy frameworks, as well as brand trust. 'China's lead is strategically grounded but not insurmountable. It stems from years of political initiatives, massive support for domestic automakers, targeted market regulation, and consistent technology transfer. Europe can remain competitive if it creates innovation-friendly frameworks, keeps international markets accessible to European manufacturers, regulates and promotes more swiftly, and maintains its focus on quality, digitalization, and sustainability,' says Sven Jung, Director of Economic Analysis & Financial Planning at the Handelsblatt Research Institute. Charging infrastructure determines everyday usability The importance of charging infrastructure is particularly evident. In China and Germany, BEV customers benefit from a high density of public charging stations, which provide reliable coverage not only in urban areas but also across rural regions. In contrast, France and the US have a patchy charging network — especially in rural areas and large cities without access to private charging — which significantly limits everyday usability and, thus, market penetration. 'For a charging infrastructure to be truly usable in everyday life, two key factors are essential. First, it must be so well-developed that drivers no longer need to plan routes around charging stations. And second, fast-charging points are crucial to ensure that charging itself doesn't result in significant time loss,' comments Sven Jung. Monetary aspects are crucial, but are heavily influenced by policy The index results also show that while monetary factors, such as vehicle prices and electricity costs, remain central to purchasing decisions, they are heavily influenced by policy. In China, electric vehicles are especially affordable due to government subsidies, low electricity prices, and cost advantages from mass production. In contrast, high electricity costs and the removal of purchase incentives in Germany reduce BEV market attractiveness. Moreover, high EU tariffs weaken the competitiveness of Chinese models. In response, manufacturers like BYD and Leapmotor are investing in production facilities in Europe. 'Price, incentives, and power: e-mobility will only reach the mass market when purchase incentives, charging infrastructure, and fair electricity prices come together — and here, also governments have a role to play. In Germany, for example, a targeted reintroduction of purchase premiums, tax incentives to regulate electricity prices, and a rapid expansion of the charging network could have a significant short-term impact. In the medium term, promoting affordable BEV models, combined with OEM innovation and scaling, as well as investment in semiconductors, battery cell production, recycling, and the development of local value chains, will be key,' explains Manuel Schuler, Global Leader Automotive and Industrial Manufacturing at BearingPoint. Trust is also a critical but often underestimated success factor Trust in manufacturers also plays a central role, especially in international brand comparisons. In all four examined markets, domestic brands perform best: BYD in China, Renault in France, VW in Germany, and Tesla in the US. With 155.9 points, BYD achieved the highest individual score in the Attractiveness Index. However, these brands lose significant attractiveness in foreign markets, highlighting the strong influence of regional brand loyalty and trust on purchase decisions. Chinese manufacturers like BYD and MG, despite their technological maturity, struggle with image issues in Europe. The trust advantage of German brands — particularly in the premium segment — remains a strategic asset, though it is increasingly under pressure, especially among younger and more brand-agnostic consumers. 'Chinese OEMs are technically competitive, but they need to build trust through better branding and a reliable local presence. Successful market entry requires a long-term commitment, competitive pricing, a strong understanding of local customer needs, and a market-specific brand strategy. Only then can they translate their technical quality into actual market success,' says Manuel Schuler. About the Study The E-Mobility Attractiveness Index was developed in 2024 by BearingPoint and the Handelsblatt Research Institute for the German market. It reflects the attractiveness of battery electric vehicles (BEVs) to potential buyers within a given market. In 2025, the index was also calculated for China, France, and the US. The index is based on a survey of drivers in each country regarding trust in manufacturers' quality promises and perceptions of digital innovation, along with objective parameters such as price, range, charging speed, electricity costs per 100 kilometers, and charging station density. These factors are weighted differently according to their importance in the purchasing decision. The evaluation includes vehicle models from various manufacturers that are either currently in demand or expected to be relevant in each country, representing a range of price segments. A portion of the manufacturers — VW, BMW, Mercedes, Porsche, Tesla, and BYD (not available in the USA) — is identical across all four countries. About the Handelsblatt Research Institute Handelsblatt Research Institute (HRI) is an independent research Institute owned by the Handelsblatt Media Group. It produces scientific studies on behalf of clients such as companies, financial investors, associations, foundations, and government agencies. It benefits from the combined scientific expertise of a 20-strong team of economists, social and natural scientists, information scientists, and historians with journalistic expertise in the preparation of the results. The Handelsblatt Research Institute works with a network of partners and specialists. It also offers desk research, competitive analysis, and market research services. About BearingPoint BearingPoint is an independent management and technology consultancy with European roots and a global reach. The company operates in three business units: Consulting, Products, and Capital. Consulting covers the advisory business with a clear focus on selected business areas. Products provides IP-driven digital assets and managed services for business-critical processes. Capital delivers M&A and transaction services. In addition, BearingPoint runs the joint venture Arcwide, focused on business transformation and consulting excellence based on IFS. BearingPoint's clients include many of the world's leading companies and organizations. The firm has a global consulting network with more than 10,000 people and supports clients in over 70 countries, engaging with them to achieve measurable and sustainable success. BearingPoint is a certified B Corporation, meeting high standards of social and environmental impact.
Business Insider
25 minutes ago
- Business Insider
British Drugs Giant AstraZeneca Pondering Stock Market Shift to the U.S.
Pharmaceutical giant AstraZeneca (AZN), the U.K.'s most valuable company, is considering moving its stock market listing to the U.S. Don't Miss TipRanks' Half-Year Sale Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week. U.K. Restrictions Chief Executive Sir Pascal Soriot, as reported by The Times, has spoken privately about his desire to leave the FTSE 100 behind and head stateside. Soriot is said to be concerned about how quickly Europe is falling behind the U.S. and China when it comes to medicine innovation. He is also known to be frustrated by the restrictions on approvals of new drugs and treatments by the state-owned National Institute for Health and Care Excellence, or NICE – such as breast cancer drug Enhertu. AstraZeneca is no stranger to the U.S., which accounts for over 40% of its $54 billion group revenues. It recently ramped up investment there both to escape tariff hits and as a move away from those U.K. and European restrictions. London Loss The loss of the firm, with a market value of around £160 billion, would be a major blow to the London stock market and will likely meet opposition from some shareholders and the U.K. government. It would follow on the heels of other firms shifting their primary listings to the U.S., such as building materials supplier CRH (CRH). 'America is important to its growth strategy and it could become an even bigger cog in the wheel,' said Dan Coatsworth, investment analyst at AJ Bell. 'The CEO seems frustrated at the lack of financial support to open new laboratories and manufacturing facilities in Europe and might see a full U.S. stock listing as a stepping stone to receiving better treatment stateside.' Is AZN a Good Stock to Buy Now?
Business Wire
an hour ago
- Business Wire
Medimaps Group Launches In Europe TBS Osteo Next-Generation Software For Advanced Bone Microarchitecture Assessment
GENEVA--(BUSINESS WIRE)--Medimaps Group S.A., a global leader in AI-driven bone microarchitecture imaging solutions, announces the European launch of its MDR-cleared next-generation TBS Osteo Advanced software. Following the product launch in the United States last month, this next milestone reflects the company's commitment to advancing osteoporosis detection and bone health management worldwide. TBS Osteo next-generation is available through a convenient subscription model, a flexible option providing customers with eligibility for software updates, new features and support services. Share The TBS Osteo Advanced software delivers refined correction for soft tissue thickness anterior to the lumbar spine, ensuring inclusivity of TBS assessment across a wide range of body phenotypes. It also introduces new system management capabilities, allowing hospitals and healthcare networks to centrally manage the TBS software on their DXA systems fleet, and to standardize workflows across multiple locations. These improvements enhance operational efficiency, streamline clinical processes, and ensure consistent patient care. TBS Osteo is available through a convenient subscription model, a flexible option providing customers with eligibility for software updates, new features and support services. This approach ensures healthcare organizations stay up to date with the latest innovations in osteoporosis care. Current TBS Osteo users have the possibility to upgrade to the next generation version and to take advantage of the new capabilities. 'The TBS Osteo next-generation software has been developed with busy radiology professionals in mind for a maximum of clinical output with a minimum of logistics. The software is seamlessly integrated into the clinical workflow and performed at time of DXA scan. This approach sets TBS Osteo apart from competition,' said Univ. Prof. Dr. Didier Hans, CEO and Co-founder of Medimaps Group. 'TBS Osteo delivers within seconds a comprehensive report combining BMD and clinical factors, providing results beyond the standard of care. Adopted by many top hospitals across the world, including in the U.S., DXA and TBS Osteo have become the gold standard to detect and monitor osteoporosis.' Since its initial launch in 2012, TBS Osteo has been widely adopted across the world, to support the assessment and management of osteoporosis. The software is backed by over 1,400 peer-reviewed publications and endorsed by more than 30 national and international osteoporosis assessment and management guidelines. In Europe, the software has received clearance from the Medical Device Regulation (MDR) and remains the only approved medical software for bone microarchitecture evaluation in clinical practice. Osteoporosis is a condition that weakens bones and increases the risk of fractures. Fractures due to osteoporosis have a devastating impact on millions of people worldwide and result in enormous socio-economic costs to society and healthcare systems. According to the International Osteoporosis Foundation, approximately 32 million Europeans aged 50 or over have osteoporosis. The annual number of osteoporotic fractures across the European Union, Switzerland, and the United Kingdom is projected to rise from 4.33 million in 2019 to 5.34 million by 2034 - an increase of over 1 million fractures annually¹. Despite the availability of effective treatments to reduce fracture risk, only 1 in 5 patients who experience an osteoporotic fracture are diagnosed or receive appropriate therapy¹. References International Osteoporosis Foundation (IOF), Last accessed: June 24, 2025 About Medimaps Group Founded by medical practitioners and clinical researchers, Medimaps combines Swiss innovation with a global presence to lead in bone health management. We provide healthcare professionals worldwide with advanced AI-driven software that enables comprehensive bone microarchitecture assessment. Our passion for musculoskeletal health is underpinned by scientific knowledge, collaborations with world-class academics, clinicians, industry partners, and direct patient engagement. The science behind our cutting-edge imaging applications and clinical evidence forms the core of our company's DNA. Medimaps Group, headquartered in Geneva, Switzerland, has offices in the United States and France. Its U.S. affiliate, Medimaps Group USA LLC, markets the company products and services. Learn more at
